Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Source: SeekingAlpha
2026-05-18 11:41:00 ET
By Diederik Stadig , Senior Economist, Healthcare & Technology
Executive summary
Marty Makary, the US Food and Drug Administration (FDA) commissioner, has been ousted just over a year into the role amid criticism from both inside and outside the Trump administration over his stance on flavoured vapes and abortion pills, among others....
Read the full article on Seeking Alpha
For further details see:
Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts
Simplify Health Care ETF
NASDAQ: PINK
PINK Trading
-1.22% G/L:
$37.8899 Last:
12,024 Volume:
$38.69 Open:
PINK Latest News
June 05, 2026 12:25:57 pm
Healthcare Giants or Medical Innovators? XLV and PINK Are Built for Different Investors.
June 02, 2026 02:57:38 pm
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors?
December 12, 2025 10:00:00 am
Simplify Provides Estimated Capital Gain Distribution Information for 2025
